PRIMARY CNS LYMPHOMA
PCNSL: HD-MTX, IBRUTINIB & CHINA ACCESS
An aggressive brain lymphoma with a distinct treatment pathway from other brain tumours — high-dose methotrexate remains the backbone, and ibrutinib has transformed the relapsed/refractory landscape.
analyticsAt a Glance
- check_circlePCNSL is DLBCL confined to the CNS — surgery plays no therapeutic role, only biopsy for diagnosis
- check_circleHD-MTX-based induction (3–8 g/m²) is the international treatment standard for PCNSL
- check_circleIbrutinib (BTK inhibitor) achieves 50–75% response rates in relapsed/refractory PCNSL
- check_circleCancerFax connects patients to specialist neuro-oncology and haematology centres in China and India
What Is Primary CNS Lymphoma and Why Is It Different from Other Brain Tumours?
Primary CNS lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma — specifically diffuse large B-cell lymphoma (DLBCL) — that arises exclusively within the central nervous system. It accounts for 2–3% of all primary brain tumours but behaves fundamentally differently from glioma or meningioma: it is an infiltrating haematological malignancy, not a solid tumour, and its management is built around systemic chemotherapy, not surgery.
“PCNSL looks like a brain tumour on MRI but is treated like lymphoma — surgery is limited to biopsy, and chemotherapy is the definitive treatment.”
Why Surgery Has No Role
PCNSL is diffusely infiltrating and multifocal at the microscopic level — complete resection is impossible and craniotomy adds morbidity without therapeutic benefit. Stereotactic biopsy confirms diagnosis; resection is not performed.
Why HD-MTX Is the Backbone
Methotrexate at high doses (3–8 g/m²) achieves effective CNS penetration via passive diffusion across the blood-brain barrier — low-dose MTX does not reach therapeutic CNS concentrations. HD-MTX is the most active single agent in PCNSL and defines all effective induction regimens.
Key Clinical Numbers in PCNSL
PCNSL outcomes have improved substantially with modern HD-MTX-based protocols and consolidation strategies — though the disease remains challenging, particularly in older and immunocompromised patients.
- 70–90%Overall response rate to HD-MTX-based inductionHD-MTX monotherapy or combination regimens (MATRix: MTX + cytarabine + thiotepa + rituximab) achieve ORR of 70–90% in newly diagnosed immunocompetent PCNSL.
- 50–75%Response rate for ibrutinib in relapsed/refractory PCNSLIbrutinib monotherapy and ibrutinib + temozolomide/rituximab combinations achieve ORR of 50–75% in R/R PCNSL — the most active agents in this setting.
- 3–4 yrsMedian OS with modern consolidation (young fit patients)Young, fit PCNSL patients completing HD-MTX induction followed by ASCT consolidation achieve median overall survival of 3–4+ years — significantly better than WBRT consolidation due to less neurotoxicity.
Key PCNSL Treatment Regimens
Treatment selection depends on patient age, performance status, immunocompetence, and disease setting — induction vs consolidation vs relapsed/refractory.
| Regimen | Setting | Key Components | Response Rate |
|---|---|---|---|
| MATRix (IELSG32) | Induction — young/fit | HD-MTX 3.5 g/m² + cytarabine + thiotepa + rituximab | ~87% ORR (CR + PR) |
| HD-MTX monotherapy | Induction — elderly/unfit | MTX 3–8 g/m² every 2 weeks × 6 cycles | ~50–65% ORR |
| R-MPV | Induction — North American standard | Rituximab + MTX + procarbazine + vincristine | ~75–90% ORR |
| ASCT consolidation | Post-induction — young/fit CR | BCNU/thiotepa or BEAM conditioning + autologous SCT | Best PFS/OS, lowest neurotoxicity |
| WBRT consolidation | Post-induction — elderly unfit for ASCT | 23.4–36 Gy WBRT | Effective but significant neurocognitive toxicity risk |
| Ibrutinib ± rituximab ± temozolomide | Relapsed/refractory | BTK inhibition — CNS penetrant | 50–75% ORR in R/R |
| Tisagenlecleucel / axicabtagene (off-label, trial) | R/R PCNSL refractory to ibrutinib | CAR-T — investigational | ~40–60% in early series — trial access recommended |
PCNSL Treatment Pathway: From Diagnosis to Consolidation
PCNSL management follows a defined pathway — biopsy first, then rapid initiation of HD-MTX-based induction, followed by response-adapted consolidation based on age and fitness.
- 1
Stereotactic Biopsy
Stereotactic needle biopsy of the most accessible enhancing lesion provides tissue for histology, immunohistochemistry (CD20, CD10, MUM1, BCL6), and molecular studies. No resection. Corticosteroids should be withheld before biopsy if possible as they are directly cytotoxic to lymphoma and may cause false-negative results.
- 2
Staging and Pre-treatment Workup
CT chest/abdomen/pelvis, bone marrow biopsy, slit-lamp examination (vitreoretinal involvement in 15–25%), CSF cytology if safe, and HIV/HBV serology. Creatinine clearance essential before HD-MTX (requires adequate renal function).
- 3
HD-MTX-Based Induction (4–6 Cycles)
MATRix or R-MPV for fit patients; HD-MTX monotherapy for elderly or unfit. Each cycle requires IV hydration, leucovorin rescue, and urinary alkalinisation — typically administered in hospital with MTX serum level monitoring.
- 4
Response Assessment MRI
Contrast-enhanced brain MRI after induction cycles 2–4 and at completion. Response classification (CR/PR/SD/PD) determines consolidation plan.
- 5
Consolidation (Age/Fitness Adapted)
CR/PR in fit patients <65–70: proceed to ASCT consolidation (BCNU/thiotepa conditioning). Elderly patients: reduced-dose WBRT (23.4 Gy) or cytarabine-based consolidation. Response to consolidation determines long-term outcome.
Ibrutinib in PCNSL: Mechanism, Evidence, and Role
Ibrutinib (a BTK inhibitor) achieves meaningful CNS penetration and targets the BCR-signalling pathway that PCNSL DLBCL cells depend upon for survival — making it the most active repurposed agent in relapsed/refractory PCNSL.
“Ibrutinib does not replace HD-MTX — but for patients who relapse after first-line therapy, it provides a second chance that nothing else has reliably offered.”
CNS Penetration of Ibrutinib
Ibrutinib reaches therapeutic CSF concentrations — critical for CNS lymphoma activity. The CSF/plasma ratio of ibrutinib is approximately 1:4, providing meaningful CNS drug exposure at standard oral dosing (560 mg/day).
Ibrutinib + Temozolomide + Rituximab
The ibrutinib + temozolomide + rituximab (R-IE or IR-Temo) combination has shown 50–70% ORR in heavily pretreated R/R PCNSL in phase 2 trials — enabling some patients to bridge to ASCT or achieve durable remission.
Frequently Asked Questions
Common questions from patients and families navigating a PCNSL diagnosis.
About PCNSL Treatment
Is PCNSL treated differently from systemic DLBCL?
Yes — significantly. Standard DLBCL regimens (R-CHOP) do not adequately penetrate the blood-brain barrier and are ineffective for PCNSL. HD-MTX at doses of 3–8 g/m² is required for CNS-active chemotherapy. PCNSL should always be managed by centres with experience in both neuro-oncology and haematological malignancy.
Can PCNSL be treated in China?
Yes. Beijing Tiantan Hospital, Peking Union Medical College Hospital (PUMCH), and Huashan Hospital Shanghai all have haematology/neuro-oncology programmes capable of delivering HD-MTX-based induction and ASCT consolidation. CancerFax can identify the appropriate centre and facilitate the full referral process for international patients.
What is the role of whole brain radiation in PCNSL today?
WBRT has been largely replaced by ASCT consolidation in fit young patients due to WBRT's significant neurotoxicity — including progressive cognitive decline and leukoencephalopathy, especially at doses ≥36 Gy. WBRT at reduced dose (23.4 Gy) remains appropriate for elderly patients who cannot undergo ASCT and who achieve CR after induction.
Is CAR-T cell therapy available for PCNSL?
CAR-T therapy for PCNSL is investigational — available through clinical trials at specialist centres. Early data from axicabtagene ciloleucel and tisagenlecleucel show activity in R/R PCNSL, with ORR around 40–60% in small series. CancerFax can identify open CAR-T trials for PCNSL and assess eligibility for international patients.
More from the Brain Tumour Treatment Resource Library
Explore related neuro-oncology and brain tumour treatment access guides.
- ↑ Brain Tumour Treatment — Complete Guide
- Brain Tumour Treatment in China: Tiantan Hospital Beijing and SPHIC
- ONC201 for H3K27M-Mutant Diffuse Midline Glioma: Eligibility and Access
- Brain Tumour Treatment Costs: China vs India vs USA
- Getting a Second Opinion on Brain Tumour Treatment Through CancerFax
- Oligodendroglioma and 1p/19q Co-Deletion: The Most Curable High-Grade Brain Tumour
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Get Expert Guidance on PCNSL Treatment Access
CancerFax reviews your MRI imaging, brain biopsy pathology, and treatment history to identify the most appropriate PCNSL protocol — and connects you with neuro-oncology and haematology centres experienced in HD-MTX and ibrutinib-based regimens, including access to clinical trials.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified neuro-oncologist or haematologist before making treatment decisions.